284 related articles for article (PubMed ID: 32125375)
1. Estimating a cost-effectiveness threshold for health care decision-making in South Africa.
Edoka IP; Stacey NK
Health Policy Plan; 2020 Jun; 35(5):546-555. PubMed ID: 32125375
[TBL] [Abstract][Full Text] [Related]
2. Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research.
Ochalek J; Lomas J
Clin Ther; 2020 Jan; 42(1):44-59.e2. PubMed ID: 31955967
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of intensive care for hospitalized COVID-19 patients: experience from South Africa.
Cleary SM; Wilkinson T; Tamandjou Tchuem CR; Docrat S; Solanki GC
BMC Health Serv Res; 2021 Jan; 21(1):82. PubMed ID: 33482807
[TBL] [Abstract][Full Text] [Related]
4. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
Eaton JW; Menzies NA; Stover J; Cambiano V; Chindelevitch L; Cori A; Hontelez JA; Humair S; Kerr CC; Klein DJ; Mishra S; Mitchell KM; Nichols BE; Vickerman P; Bakker R; Bärnighausen T; Bershteyn A; Bloom DE; Boily MC; Chang ST; Cohen T; Dodd PJ; Fraser C; Gopalappa C; Lundgren J; Martin NK; Mikkelsen E; Mountain E; Pham QD; Pickles M; Phillips A; Platt L; Pretorius C; Prudden HJ; Salomon JA; van de Vijver DA; de Vlas SJ; Wagner BG; White RG; Wilson DP; Zhang L; Blandford J; Meyer-Rath G; Remme M; Revill P; Sangrujee N; Terris-Prestholt F; Doherty M; Shaffer N; Easterbrook PJ; Hirnschall G; Hallett TB
Lancet Glob Health; 2014 Jan; 2(1):e23-34. PubMed ID: 25104632
[TBL] [Abstract][Full Text] [Related]
5. Moving towards malaria elimination in southern Mozambique: Cost and cost-effectiveness of mass drug administration combined with intensified malaria control.
Cirera L; Galatas B; Alonso S; Paaijmans K; Mamuquele M; Martí-Soler H; Guinovart C; Munguambe H; Luis F; Nhantumbo H; Montañà J; Bassat Q; Candrinho B; Rabinovich R; Macete E; Aide P; Alonso P; Saúte F; Sicuri E
PLoS One; 2020; 15(7):e0235631. PubMed ID: 32628741
[TBL] [Abstract][Full Text] [Related]
6. Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures.
Pichon-Riviere A; Drummond M; Palacios A; Garcia-Marti S; Augustovski F
Lancet Glob Health; 2023 Jun; 11(6):e833-e842. PubMed ID: 37202020
[TBL] [Abstract][Full Text] [Related]
7. Informing a cost-effectiveness threshold for Saudi Arabia.
Al-Jedai AH; Lomas J; Almudaiheem HY; Al-Ruthia YSH; Alghamdi S; Awad N; Alghamdi A; Alowairdhi MA; Alabdulkarim H; Almadi M; Bunyan RF; Ochalek J
J Med Econ; 2023; 26(1):128-138. PubMed ID: 36576804
[TBL] [Abstract][Full Text] [Related]
8. Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research.
Woods B; Revill P; Sculpher M; Claxton K
Value Health; 2016 Dec; 19(8):929-935. PubMed ID: 27987642
[TBL] [Abstract][Full Text] [Related]
9. Active Tuberculosis Screening via a Mobile Health App in Myanmar: Incremental Cost-Effectiveness Evaluation.
Htet KKK; Phyu AN; Zayar NN; Chongsuvivatwong V
JMIR Form Res; 2023 Nov; 7():e51998. PubMed ID: 37948119
[TBL] [Abstract][Full Text] [Related]
10. Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach.
Ochalek J; Wang H; Gu Y; Lomas J; Cutler H; Jin C
Pharmacoeconomics; 2020 Dec; 38(12):1319-1331. PubMed ID: 32856280
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study.
Lin JK; Moran AE; Bibbins-Domingo K; Falase B; Pedroza Tobias A; Mandke CN; Kazi DS
Lancet Glob Health; 2019 Oct; 7(10):e1346-e1358. PubMed ID: 31477544
[TBL] [Abstract][Full Text] [Related]
12. Cost per DALY averted in low, middle- and high-income countries: evidence from the global burden of disease study to estimate the cost-effectiveness thresholds.
Daroudi R; Akbari Sari A; Nahvijou A; Faramarzi A
Cost Eff Resour Alloc; 2021 Feb; 19(1):7. PubMed ID: 33541364
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study.
Lee H; Park SY; Clark A; Debellut F; Pecenka C; Kim DS; Kim HM; Kim JH; Cho H; Kim AY; Lee M; Jung SY; Seong BL; Kang HY
Vaccine; 2019 Aug; 37(35):4987-4995. PubMed ID: 31326252
[TBL] [Abstract][Full Text] [Related]
14. The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up.
Hecht R; Hiebert L; Spearman WC; Sonderup MW; Guthrie T; Hallett TB; Nayagam S; Razavi H; Soe-Lin S; Vilakazi-Nhlapo K; Pillay Y; Resch S
Health Policy Plan; 2018 May; 33(4):528-538. PubMed ID: 29529282
[TBL] [Abstract][Full Text] [Related]
15. An economic case study of the control of dog-mediated rabies by an animal welfare organisation in Jaipur, India.
Larkins AJ; Reece JF; Shaw APM; Thrusfield MV
Prev Vet Med; 2020 Oct; 183():105120. PubMed ID: 32890917
[TBL] [Abstract][Full Text] [Related]
16. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
[TBL] [Abstract][Full Text] [Related]
17. Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds.
Robinson LA; Hammitt JK; Chang AY; Resch S
Health Policy Plan; 2017 Feb; 32(1):141-145. PubMed ID: 27452949
[TBL] [Abstract][Full Text] [Related]
18. Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trial.
Thomas R; Probert WJM; Sauter R; Mwenge L; Singh S; Kanema S; Vanqa N; Harper A; Burger R; Cori A; Pickles M; Bell-Mandla N; Yang B; Bwalya J; Phiri M; Shanaube K; Floyd S; Donnell D; Bock P; Ayles H; Fidler S; Hayes RJ; Fraser C; Hauck K;
Lancet Glob Health; 2021 May; 9(5):e668-e680. PubMed ID: 33721566
[TBL] [Abstract][Full Text] [Related]
19. Scaling up antivenom for snakebite envenoming in the Brazilian Amazon: a cost-effectiveness analysis.
Zimmerman A; Monteiro W; Nickenig Vissoci JR; Smith ER; Rocha T; Sachett J; Wen FH; Staton C; Gerardo CJ; Ogbuoji O
Lancet Reg Health Am; 2024 Jan; 29():100651. PubMed ID: 38124996
[TBL] [Abstract][Full Text] [Related]
20. A cost-effectiveness analysis of South Africa's COVID-19 vaccination programme.
Edoka I; Silal S; Jamieson L; Meyer-Rath G
Vaccine; 2024 May; ():. PubMed ID: 38824084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
